✦ LIBER ✦

Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind placebo-controlled study

✍ Scribed by G. Chouinard; L. Annable; R. Fontaine; L. Solyom

Publisher: Springer
Year: 1982
Tongue: English
Weight: 472 KB
Volume: 77
Category: Article
ISSN: 0033-3158
DOI: 10.1007/bf00464571

No coin nor oath required. For personal study only.

✦ Synopsis

In a double-blind controlled study lasting 8 weeks, 50 anxious psychoneurotic outpatients with a primary diagnosis of generalized anxiety or panic disorder were randomly assigned to alprazolam (n = 30), a new benzodiazepine, or placebo (n = 20), after a washout period of 1 week. Alprazolam at dosages between 0.25 and 3 mg/day was found to be significantly better than placebo in the treatment of either disorder. The finding that alprazolam was effective in the treatment of panic disorder is of interest as this diagnostic category is usually treated with tricyclic antidepressants or MAO inhibitors.

📜 SIMILAR VOLUMES

Escitalopram in the treatment of general

Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study

✍ Jonathan R.T. Davidson; Anjana Bose; Andrew Korotzer; Hongjie Zheng 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with depression, panic disorder, and social anxiety disorder. This study was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of generalized anxiety disorder (GAD). Outpatients (1

Ritanserin in the treatment of generaliz

Ritanserin in the treatment of generalized anxiety disorders: A placebo-controlled trial

✍ E. A. Pangalila-Ratu Langi; A. A. I. Jansen 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 2 views

In a double-blind trial, 22 patients treated with 5 mg b.i.d. of the selective serotonin-S2 antagonist ritanserin for 4 weeks were compared with 26 patients treated with placebo for generalized anxiety disorder (DSM 111: 300.02). Symptoms were assessed using the Hamilton Anxiety Rating Scale (HARS)

Treatment of primary fibrositis/fibromya

Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study

✍ I. Jon Russell; Ellen M. Fletcher; Joel E. Michalek; Patrick C. McBroom; G. Gene 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 845 KB

Treatment of primary fibrositis/fibromya

Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study

✍ I. Jon Russell; Ellen M. Fletcher; Joel E. Michalek; Patrick C. McBroom; G. Gene 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 845 KB

A multidimensional evaluation of 78 patients with primary fibrositis/fibromyalgia syndrome (PFS) revealed no significant relationship between clinical measures of physical discomfort and psychological measures. This observation provided evidence against the notion that the pain of PFS has a psycholo

Treatment of postinfectious olfactory di

Treatment of postinfectious olfactory disorders with minocycline: A double-blind, placebo-controlled study

✍ Jens Reden; Birgit Herting; Katja Lill; Robert Kern; Thomas Hummel 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

Objectives/Hypothesis: Infection of the upper respiratory tract is one of the most common causes of olfactory loss. One of the possible underlying pathologic pathways is an increase of apoptosis of olfactory receptor neurons. Therefore, treatment with the antibiotic minocycline, which has been shown

Alprazolam SR in the treatment of genera

Alprazolam SR in the treatment of generalized anxiety: a multicentre controlled study with bromazepam

✍ M. Luisa Figueira 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

A multicentre, double-blind, randomized trial compared the ecacy of a sustained-release formulation of alprazolam with bromazepam in the treatment of generalized anxiety. One hundred and twenty-one outpatients were randomly assigned to three weeks of active treatment with alprazolam SR (2 mg once da